Department of Rheumatology, Regional Hospital of Orleans, 45067 Orleans, France.
University of Orleans, EA 4708 - I3MTO Laboratory, 45067 Orleans, France.
Immunotherapy. 2021 Jan;13(1):19-33. doi: 10.2217/imt-2020-0225. Epub 2020 Nov 9.
Psoriatic arthritis (PsA) is a heterogeneous chronic rheumatic disorder with numerous phenotypic facets. A better in deep understanding of the pathophysiologic mechanisms leading to psoriasis and PsA has contributed to the introduction of novel therapeutic agents. IL-17 is at the heart and a critical factor in the onset of PsA. Ixekizumab, a high-affinity monoclonal antibody against IL-17 A, has been approved by the US FDA in March 2016 for baseline psoriasis and Dec 2017 for PsA; by the EMA in April 2016 and January 2018, respectively. This article reviews the published data relating to ixekizumab efficacy and safety in the PsA treatment.
银屑病关节炎（PsA）是一种异质性的慢性风湿性疾病，具有众多表型特征。对导致银屑病和 PsA 的病理生理机制的深入了解，有助于引入新型治疗药物。IL-17 是银屑病关节炎发病的核心和关键因素。IL-17A 的高亲和力单克隆抗体依奇珠单抗于 2016 年 3 月获得美国食品和药物管理局（FDA）批准，用于基线期银屑病治疗；于 2017 年 12 月获得 FDA 批准，用于银屑病关节炎治疗；于 2016 年 4 月和 2018 年 1 月分别获得欧洲药品管理局（EMA）和人用医药产品委员会（CHMP）批准。本文综述了依奇珠单抗治疗银屑病关节炎的疗效和安全性的已发表数据。
